Previous 10 | Next 10 |
FSD Pharma ( NASDAQ: HUGE ) has announced that the company has received confirmation from The Nasdaq that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule. On Feb. 14, 2023, Staff notified the company that for the last ...
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“ FSD Pharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory...
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced the launch of a new ...
FSD Pharma ( NASDAQ: HUGE ) said it launched of a new research and development program focused on alcohol misuse. "FSD Pharma’s existing pipelines and research priorities in brain and inflammatory disorders, including mental health, provides a natural extension to investigate t...
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“ FSD Pharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory...
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has received a No Objection Letter from Health Can...
VANCOUVER, British Columbia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabol...
The shares of Canadian biotech FSD Pharma ( NASDAQ: HUGE ) rose for the fourth consecutive session on Tuesday after announcing that Canada greenlighted its Phase 1 trial for multiple sclerosis candidate LUCID-21-302. Issuing a No Objection Letter (NOL), Health Canada has granted the r...
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has received notification that it can move forward...
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“ FSD Pharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory...
News, Short Squeeze, Breakout and More Instantly...
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has been featured in a news report published by 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of finan...
Denver, Colorado--(Newsfile Corp. - July 25, 2024) - 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and information, today publishes a news report highlighting functional beverage market developments, featuring FSD Pharma (NASDAQ: HUGE...
2024-07-25 08:16:52 ET DENVER, Colo., Jul 25, 2024 ( 247marketnews.com )- Coca-Cola (NYSE: KO ) , FSD Pharma (NASDAQ: HUGE ), and Celsius Holdings, Inc. (NASDAQ: CELH ) Sometimes, there are some winning streaks that are so strong that even...